Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) Share Price Falls 8.95% Today

Ambalal Sarabhai Enterprises Ltd. traded at Rs 40.91, down 8.95% today, with a market capitalisation of Rs 350.06 crore.

Ambalal Sarabhai Enterprises Ltd. Share Price came under pressure on 13 August 2026, with the stock falling 8.95% to Rs 40.91 from the previous close of Rs 44.93. With a market capitalisation of Rs 350.06 crore, the company sits in the Micro Cap bucket, making the move notable enough to enter the day’s qualifying price-fall screen. For investors tracking Ambalal Sarabhai Enterprises Ltd. Share Price Today, the decline stands out because the fall was broad through the session rather than limited to a brief opening dip.

The stock opened at Rs 43 and moved within a day range of Rs 40.19 to Rs 43.26, showing that sellers retained control after the open. Total traded volume across exchanges stood at 4,25,211 shares, including 59,748 shares on BSE and 3,65,463 shares on NSE, while BSE turnover was Rs 0.24 crore. In Stock Market Today and Share Market Today screens, such moves typically draw attention because they combine a visible share price decline with measurable trading participation.

The supplied data confirms the price event but does not establish a company-specific catalyst. That matters because Ambalal Sarabhai Enterprises Ltd. Stock News is currently being driven by verified market action rather than a stated earnings surprise, management announcement or sector-specific trigger in the input data. Univest notes that investors should separate the day’s price action from the longer-term fundamental picture, especially in a Healthcare name where valuation, profitability and peer comparison can look very different from intraday momentum. That makes today’s move relevant not only as Ambalal Sarabhai Enterprises Ltd. Share Price News, but also as a fresh stock analysis and fundamental analysis checkpoint.

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 40.91
Previous Close	Rs 44.93
Today's Change	Rs -4.02 (-8.95%)
Day Open	Rs 43
Day High	Rs 43.26
Day Low	Rs 40.19
Current Volume (BSE)	59,748
BSE Traded Volume	59,748
NSE Traded Volume	3,65,463
Combined NSE + BSE Volume	4,25,211
Turnover	Rs 0.24 crore
Market Capitalisation	Rs 350.06 crore
Market Cap Category	Micro Cap

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) traded at Rs 40.91. versus the previous close of Rs 44.93, a fall of 8.95%. The stock opened at Rs 43, reached Rs 43.26, touched Rs 40.19. Reported volume was 59,748.

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 350.06 crore
P/E Ratio	19.34x
P/B Ratio	2.17x
ROE	48.74%
ROCE	45.53%
EPS	Rs 2.32
Dividend Yield	0%

Ambalal Sarabhai Enterprises Ltd. was valued at a P/E ratio of 19.34x, a P/B ratio of 2.17x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 48.74% and ROCE of 45.53%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 2.32, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Ambalal Sarabhai Enterprises Ltd. Fundamental Analysis presents an interesting contrast to the day’s weak price action. The company’s market capitalisation stands at Rs 350.06 crore, placing it above the same-industry median market cap of Rs 147.59 crore but below the industry average of Rs 490.67 crore. That gives the company a visible presence within the Pharmaceuticals & Drugs space even though it remains a Micro Cap in market classification.

On valuation, the stock trades at a P/E ratio of 19.34 and a P/B ratio of 2.17. Those numbers are important because the same-industry benchmark shows a median P/E of 25.27 and an average P/E of 69.01 across 103 companies with available P/E data. Against that backdrop, Ambalal Sarabhai Enterprises Ltd. Share Price is not carrying the kind of earnings multiple seen in many richly valued pharma names in the benchmark set. On book value comparison, the company P/B of 2.17 is above the industry median of 1.82 but below the average of 2.44 across 135 companies, placing it closer to the middle of the sector range than to either extreme.

Profitability metrics are stronger than the valuation multiples might first suggest. ROE stands at 48.74% and ROCE at 45.53%, both well above the same-industry medians of 10.49% and 12.97%, and also above the respective averages of 8.09% and 15.63%. For investors reading Ambalal Sarabhai Enterprises Ltd. Stock Analysis, this is one of the most striking parts of the data set: the company is showing much higher returns on equity and capital employed than the broader benchmark universe.

EPS is Rs 2.32, which gives a direct earnings-per-share reference point for the current stock price, while dividend yield is 0. That means the market’s present interest in the stock is linked more to earnings and capital efficiency than to historical cash payout. Univest would frame this as a mixed day for the stock: the market delivered a sharp share price decline, yet the available fundamental ratios still show profitability levels that screen strongly relative to the broader industry set. That contrast makes ownership, sector positioning and peer comparison especially relevant for interpreting Ambalal Sarabhai Enterprises Ltd. Share Price Today.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	19.34x
Benchmark Median P/E	25.27x
Benchmark Average P/E	69.01x
Benchmark P/E Range	3.44x to 3,374.81x
Company P/B Ratio	2.17x
Benchmark Median P/B	1.82x
Company ROE	48.74%
Benchmark Median ROE	10.49%
Company ROCE	45.53%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 350.06 crore
Benchmark Median Market Cap	Rs 147.59 crore

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a P/E ratio of 19.34x, which is below the benchmark median of 25.27x, a difference of -23.47%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a ROE of 48.74%, which is above the benchmark median of 10.49%, a difference of +364.63%. Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a ROCE of 45.53%, which is above the benchmark median of 12.97%, a difference of +251.04%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Ambalal Sarabhai Enterprises Ltd. operates in Healthcare, specifically Pharmaceuticals & Drugs, and the sector snapshot offers a useful benchmark for interpreting today’s fall. Within a same-industry comparison set of 136 companies, the stock’s valuation and profitability metrics sit in a distinctive position: its earnings multiple is below the sector median, while its return ratios are materially above both median and average levels.

The benchmark scope here is the same industry, covering 136 companies. Ambalal Sarabhai Enterprises Ltd. Share Price is tied to a company P/E of 19.34, versus an industry median P/E of 25.27, an average of 69.01, a minimum of 3.44 and a maximum of 3374.81 across 103 companies with available P/E data. That range shows how widely valuations can vary inside Pharmaceuticals & Drugs. Relative to that distribution, the company’s P/E sits below both the median and average, suggesting it is not priced at the premium end of the industry on earnings.

On a price-to-book basis, the company’s 2.17 compares with a benchmark median of 1.82 and average of 2.44 across 135 companies, with the full range running from -16.89 to 16.74. That puts the stock slightly above the median book multiple but still below the broader average. Profitability tells a clearer story. Company ROE of 48.74% is far above the median ROE of 10.49% and average of 8.09%, while ROCE of 45.53% is well ahead of the median 12.97% and average 15.63%.

Market capitalisation context is also relevant. At Rs 350.06 crore, the company is above the industry median market cap of Rs 147.59 crore but below the average of Rs 490.67 crore, in a sector where the market cap range extends from Rs 6.55 crore to Rs 3,027.48 crore. Univest reads this sector setup as broadly supportive of investor interest in the stock despite today’s weakness: the valuation is not stretched versus the industry median, while profitability metrics remain unusually strong for the benchmark set. That is why Ambalal Sarabhai Enterprises Ltd. Share Price News deserves more than a headline-only reading.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,027.48	0	0.77	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,958.04	68.39	10.82	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.2	15.22	16.15
Sai Parenteral's Ltd.	SAIPARENT	2,559.74	171.25	3.13	13.9	12.97
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,474.06	44.25	1.76	-0.78	8.31

Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a P/E ratio of 19.34x compared with the displayed peer median of 44.25x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 48.74% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at 45.53% versus the displayed peer median of 12.97%, providing a capital-efficiency comparison. Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) has a market capitalisation of Rs 350.06 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Ambalal Sarabhai Enterprises Ltd. Share Price also gains context when stacked against listed peers in Pharmaceuticals & Drugs. The company’s market capitalisation of Rs 350.06 crore is smaller than peers such as Dishman Carbogen Amcis Ltd. at Rs 3,027.48 crore, Beta Drugs Ltd. at Rs 2,958.04 crore, Hikal Ltd. at Rs 2,686.72 crore, Sai Parenteral's Ltd. at Rs 2,559.74 crore and Hester Biosciences Ltd. at Rs 2,112.08 crore. So, investors are comparing a smaller-cap business against significantly larger listed names in the same industry.

On valuation, Ambalal Sarabhai Enterprises Ltd. trades at a P/E of 19.34. That is lower than Beta Drugs at 68.39, Sai Parenteral's at 171.25, Ind-Swift Laboratories at 44.25 and NGL Fine-Chem at 43.80, but above Hester Biosciences at 15.32. This places the stock on the lower side of the available peer earnings multiples rather than at the premium end.

The profitability comparison is even more notable. Ambalal Sarabhai Enterprises Ltd. reports ROE of 48.74%, comfortably above Beta Drugs at 18.65%, Hikal at 15.22%, Sai Parenteral's at 13.90%, Solara Active Pharma Sciences at 17.23%, NGL Fine-Chem at 27.90% and Hester Biosciences at 16.17%. Its ROCE of 45.53% is also ahead of Beta Drugs at 22.17%, Hikal at 16.15%, Sai Parenteral's at 12.97%, Ind-Swift Laboratories at 8.31%, Solara at 15.34%, NGL Fine-Chem at 33.91% and Hester Biosciences at 14.12%.

P/B at 2.17 looks relatively moderate beside Beta Drugs at 10.82, NGL Fine-Chem at 6.40, Sakar Healthcare at 6.22 and Hester Biosciences at 4.59, while remaining above Dishman Carbogen Amcis at 0.77 and Ind-Swift Laboratories at 1.76. On the supplied numbers alone, the peer picture shows a stock with smaller market size, comparatively restrained valuation and stronger return ratios than several larger peers. That combination helps explain why Ambalal Sarabhai Enterprises Ltd. Stock News can stay on investor watchlists even on a day marked by price falls.

Why Investors Are Watching Ambalal Sarabhai Enterprises Ltd.

Investors are watching this name because today’s share price decline was large enough to push it into the market’s qualifying decliner screen, while the underlying valuation and profitability metrics still look notable relative to the same-industry benchmark and listed peers. In other words, the day’s weak momentum is happening in a stock whose return profile is stronger than many comparable pharmaceutical names.

• Verified price action: the stock fell 8.95% to Rs 40.91 from Rs 44.93, after opening at Rs 43 and touching a low of Rs 40.19.
• Trading participation: total volume reached 4,25,211 shares, including 3,65,463 on NSE and 59,748 on BSE, with BSE turnover of Rs 0.24 crore.
• Valuation context: P/E of 19.34 is below the same-industry median of 25.27, while P/B of 2.17 is above the median of 1.82 but below the average of 2.44.
• Profitability profile: ROE of 48.74% and ROCE of 45.53% are both materially above industry medians and averages.
• Sector positioning: the company’s market cap of Rs 350.06 crore is above the industry median market cap of Rs 147.59 crore.

What investors should monitor next is whether Ambalal Sarabhai Enterprises Ltd. Share Price stabilises after this bout of selling pressure or continues to stay among Stocks Under Pressure. Univest would also watch whether the gap between strong profitability ratios and weak same-day price action narrows through later market updates, because that tension is central to the current Ambalal Sarabhai Enterprises Ltd. Share Price Update.

About Ambalal Sarabhai Enterprises Ltd.

Ambalal Sarabhai Enterprises Ltd. is part of the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. Based on the supplied data, the stock is being analysed in the context of listed pharmaceutical businesses where investors often compare valuation multiples, profitability ratios and market capitalisation against a broad same-industry peer set.

At a market value of Rs 350.06 crore, the company sits in a part of the industry that is large enough to be compared with established listed pharma businesses, but still small enough to be tracked as a Micro Cap in market screens. That matters because smaller companies can see sharper day-to-day price swings, and those moves often receive closer scrutiny when they occur inside sectors like Healthcare where peer valuations can vary widely.

The current Ambalal Sarabhai Enterprises Ltd. Share Price conversation is therefore not only about a one-day fall. It is also about how a Pharmaceuticals & Drugs company with a P/E of 19.34, P/B of 2.17, ROE of 48.74%, ROCE of 45.53% and EPS of Rs 2.32 compares with a larger universe of listed sector names. Univest sees the company’s market position through that lens: a smaller-cap healthcare stock being judged simultaneously on market action, financial efficiency and relative valuation within its industry. For readers following Ambalal Sarabhai Enterprises Ltd. Latest News, that industry placement is the key context behind today’s move.

Track Ambalal Sarabhai Enterprises Ltd. Share Price on Univest

Use Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors following Ambalal Sarabhai Enterprises Ltd. Share Price can use Univest to track live share price moves, daily percentage change, market capitalisation, valuation ratios and broader stock performance context in one place. The platform helps users monitor metrics such as P/E ratio, P/B ratio, ROE, ROCE, EPS, dividend yield, 52-week levels and sector comparison alongside regular market updates.

For Ambalal Sarabhai Enterprises Ltd. Share Price Today, that matters because a sharp one-day decline can look very different once it is placed next to peer valuation, industry benchmark data and market-cap context. Univest is useful not just for Ambalal Sarabhai Enterprises Ltd. Stock News, but also for following technical context, fundamental analysis and ongoing stock analysis without relying only on price headlines.

Frequently Asked Questions

Why is Ambalal Sarabhai Enterprises Ltd. Share Price falling today?

Ans. The supplied data confirms that Ambalal Sarabhai Enterprises Ltd. Share Price fell 8.95% to Rs 40.91 from Rs 44.93. It verifies the market move and trading activity, but it does not establish a company-specific catalyst for today’s decline.

What is Ambalal Sarabhai Enterprises Ltd. Share Price Today?

Ans. Ambalal Sarabhai Enterprises Ltd. Share Price Today is Rs 40.91. The stock was down Rs 4.02 or 8.95% versus the previous close of Rs 44.93, after trading between Rs 40.19 and Rs 43.26 during the session.

How much market capitalisation does Ambalal Sarabhai Enterprises Ltd. have?

Ans. The company’s market capitalisation stands at Rs 350.06 crore. That places it in the Micro Cap category, while also putting it above the same-industry median market capitalisation of Rs 147.59 crore in Pharmaceuticals & Drugs.

What does today’s intraday range show for the stock?

Ans. The stock opened at Rs 43, touched a high of Rs 43.26 and fell to a low of Rs 40.19. With the last traded price at Rs 40.91, the session reflected sustained weakness after the opening trade.

How active was trading in Ambalal Sarabhai Enterprises Ltd. today?

Ans. Total traded volume stood at 4,25,211 shares, including 3,65,463 shares on NSE and 59,748 shares on BSE. BSE turnover was Rs 0.24 crore, showing that the stock decline was accompanied by visible exchange participation.

Is Ambalal Sarabhai Enterprises Ltd. expensive on P/E compared with its industry?

Ans. The company trades at a P/E of 19.34, which is below the same-industry median P/E of 25.27 and well below the average of 69.01. On the supplied benchmark data, it does not screen at a premium earnings multiple.

How does the company compare on P/B ratio?

Ans. Ambalal Sarabhai Enterprises Ltd. has a P/B ratio of 2.17. That is above the same-industry median of 1.82 but below the average of 2.44, placing the stock in a middle range on book-value valuation.

What do ROE and ROCE indicate for Ambalal Sarabhai Enterprises Ltd.?

Ans. ROE is 48.74% and ROCE is 45.53%, both materially above the industry median levels of 10.49% and 12.97%. These figures indicate stronger capital efficiency than many companies in the same Pharmaceuticals & Drugs universe.

What is the EPS and dividend yield of Ambalal Sarabhai Enterprises Ltd.?

Ans. The company’s EPS is Rs 2.32 and its dividend yield is 0. This means the current data highlights earnings per share as a key metric, while historical yield does not presently add to the stock’s income profile.

How does Ambalal Sarabhai Enterprises Ltd. compare with peers?

Ans. Compared with peers such as Beta Drugs, Hikal, Sai Parenteral's and Hester Biosciences, the company has a smaller market cap at Rs 350.06 crore, but its ROE and ROCE are higher than several of those larger pharmaceutical names.